CMO rises from biotech's ashes

Introgen Therapeutics, which filed for bankruptcy protection late last year, is getting a second shot at life, of sorts.

Houston investors have purchased the company's manufacturing-related assets, reports the Houston Business Journal, and from them formed contract manufacturer Vivante GMP Solutions. At bankruptcy, the Introgen assets were divided into three: manufacturing patents, therapeutic drug assets, and manufacturing-related assets. The investors took advantage of the latter, which include a facility and documentation required to manufacture third-party biologic drugs and clinical trials.

Vivante's focus is biologics for academic institutions and biotech companies. According to the press report, several biotechs have engaged the CMO, and it retained customers throughout the bankruptcy, as an Introgen subsidiary.

- see the article

Suggested Articles

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

The FDA recently asked five drug manufacturers to recall the commonly used diabetes med metformin. With COVID-19 raging, is metformin just the start?

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.